Investigational drug · Phase 2
TRS005
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for CD20-positive Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL).
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 22, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "TRS005"
First trial start
2025
Sep 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TRS005", any sponsor or status.
Conditions studied
As listed on its trial records.
- CD20-positive Diffuse Large B-Cell Lymphoma
- Diffuse Large B-Cell Lymphoma (DLBCL)
Approved drugs for the same conditions: Lymphoma (non-Hodgkin) · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "TRS005" as an intervention, largest first.
- A Phase 1 Study of TRS005 in Patients With R/R CD20-positive B-NHL.Active, not recruiting
Zhejiang Teruisi Pharmaceutical Inc.Industry
NCT05395533 · 147 participants · Start Sep 8, 2020 · Primary completion Jul 31, 2025
Drug: Recombinant CD20 monoclonal antibody-MMAE conjugte for injection · For: CD20-positive B-cell Non-Hodgkin Lymphoma
Sites: Beijing, China; Guangzhou, China; Zhengzhou, China · 6 sites in all
- A Phase 2 Study of TRS005 in Patients With CD20-positive R/R DLBCL.Not yet recruiting
Zhejiang Teruisi Pharmaceutical Inc.Industry
NCT06886139 · 139 participants (planned) · Start Sep 2025 · Primary completion Jan 2027
Drug: TRS005 · For: CD20-positive Diffuse Large B-Cell Lymphoma
Sites: Beijing, China
- A Phase I/II Study of TRS005 in Combination With Cyclophosphamide, Doxorubicin, and Prednisone(T-CHP) in Previously Untreated Patients With CD20-positive DLBCLNot yet recruiting
Zhejiang Teruisi Pharmaceutical Inc.Industry
NCT07035379 · 66 participants (planned) · Start Sep 1, 2025 · Primary completion Sep 1, 2026
Drug: TRS005; Cyclophosphamide and 2 more · For: Diffuse Large B-Cell Lymphoma (DLBCL)
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
- CD20-directed antibody-drug conjugates in non-hodgkin lymphoma: translating preclinical promise into clinical reality.
Omidvar L, Mer AH, Mirzaei Y, et al. · J Hematol Oncol 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.